The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.
Rusfertide demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% vs 18.5% of patients with phlebotomy-dependent polycythemia vera who received placebo, meeting the primary end point of the phase 2 REVIVE trial.
Clinical Response and Durability of Response of Rusfertide (PTG-300) ... pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
NEWARK, CA / ACCESSWIRE / June 9, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Ronald Hoffman, MD, Icahn School of Medicine at Mount Sinai,
Protagonist Therapeutics (PTGX) Reports Publication of Clinical Response and Durability of Response of Rusfertide streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.